Crohn's Disease trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Crohn's Disease. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 3 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyNCT06681324Number of participants with adverse events | Phase 2 | Active, not recruiting | 2026-08-20 | today | 2026-06-01 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNCT07421258observationalPercentage of Participants Managed Using Treat-to-Target (T2T) | — | Recruiting | Sep 2026 | ≤ 41 d | 2026-03-27 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in JapanNCT06023030observationalPercentage of Participants with Drug Related Serious Infections | — | Recruiting | Nov 2026 | ≤ 102 d | 2026-02-24 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SNY | Sanofi | A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's DiseaseNCT06958536Percentage of participants who achieve endoscopic response at Week 16 | Phase 2 | Recruiting | 2026-12-17 | in 119 d | 2026-03-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Crohn's Disease
most recently updated first132 studies match. Showing the first 100 of 132 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | $457.5B | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseaseNCT03105102Sub-Study 1: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission | Phase 3 | Active, not recruiting | Drug: Placebo for Risankizumab SC, Risankizumab IV, Placebo for Risankizumab IV, Risankizumab SC, Risankizumab On-Body Injector (OBI) | Crohn's Disease | 1,336 | 2018-04-09 | Feb 2029 | ≤ 923 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseNCT02782663results2026-08-13Percentage of Participants Achieving Endoscopic Remission at Month 12 | Phase 2 | Completed | Drug: ABT-494 | Crohn's Disease (CD) | 107 | 2016-05-18 | 2025-07-18actual | — | 2026-08-13 |
| STTK | Shattuck Labs, Inc. | $748M | A Study of SL-325 in Crohn's Disease PatientsNCT07753850Proportion of participants who achieve endoscopic response | Phase 2 | Not yet recruiting | Drug: SL-325, Placebo | Crohn's Disease | 232 | Oct 2026 | Jul 2028 | ≤ 711 d | 2026-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseNCT04232553results2025-12-15Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study) | Phase 3 | Active, not recruiting | Drug: Mirikizumab | Crohn's Disease | 996 | 2020-06-22 | 2024-11-28actual | — | 2026-08-11 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)NCT04844606Percentage of Participants with UC in Modified Mayo Score (MMS) Clinical Remission | Phase 3 | Recruiting | Drug: Mirikizumab, Mirikizumab | Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease | 150 | 2021-05-26 | Dec 2030 | ≤ 1,594 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's DiseaseNCT05509777Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52 | Phase 3 | Recruiting | Drug: Mirikizumab | Crohn's Disease | 90 | 2024-03-13 | Dec 2027 | ≤ 498 d | 2026-08-07 |
| LLY | Eli Lilly and Company | $1.15T | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightNCT06937099Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction | Phase 3 | Recruiting | Drug: Mirikizumab, Mirikizumab, Tirzepatide, Placebo | Crohn's Disease, Obesity or Overweight | 290 | 2025-06-26 | May 2028 | ≤ 650 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseNCT07483073Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA) | Phase 2 | Recruiting | Drug: Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089 | Colitis, Ulcerative, Crohn Disease | 60 | 2026-05-04 | Jun 2027 | ≤ 314 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseNCT07483099Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response | Phase 2 | Recruiting | Drug: LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC) | Crohn Disease | 60 | 2026-05-04 | Jun 2027 | ≤ 314 d | 2026-08-06 |
| AZN | AstraZeneca | — | Phase IIa Study Evaluating AZD7798 in Crohn's DiseaseNCT06450197CDAI remission | Phase 2 | Active, not recruiting | Drug: AZD7798 · Other: Placebo | Moderate to Severe Crohn's Disease | 120 | 2024-08-28 | 2026-04-30actual | — | 2026-08-04 |
| LLY | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | $1.15T | A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's DiseaseNCT06226883Proportion of participants with endoscopic response at Week 14 as determined using the Simple Endoscopic Score-CD (SES-CD) | Phase 2 | Recruiting | Drug: Placebo, MORF-057 | Inflammatory Bowel Diseases, Crohn's Disease | 385 | 2024-07-18 | Sep 2028 | ≤ 772 d | 2026-07-20 |
| ABBV | AbbVie | $457.5B | Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisNCT07697456Crohn's Disease Specific: Percentage of Participants Achieving Endoscopic Remission | Phase 2 | Not yet recruiting | Drug: Risankizumab, Trosunilimab, ABBV-701 | Crohn's Disease, Ulcerative Colitis | 2,000 | 2026-07-24 | Oct 2031 | ≤ 1,898 d | 2026-07-13 |
| CELU | Celularity Incorporated | $21M | PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's DiseaseNCT01155362results2026-07-07Percentage of Subjects With Clinical Response Based on Crohn's Disease Activity Index (CDAI) at Both Week 4 and Week 6 | Phase 2 | Completed | Biological: Human Placenta-Derived Cells PDA001 Intravenous Infusion · Drug: Vehicle Control | Crohn's Disease | 50 | Aug 2010 | Feb 2012actual | — | 2026-07-07 |
| PFE | Pfizer | $155.3B | A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's DiseaseNCT04173273results2026-07-01Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA | Phase 2/3 | Terminatedsponsor's stated reason: The study was prematurely discontinued due to a lack of efficacy in sub-study 1 | Drug: Etrasimod, Etrasimod, Placebo | Crohn's Disease | 379 | 2020-01-06 | 2025-04-23actual | — | 2026-07-01 |
| SNY | Sanofi | — | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseaseNCT07184931Sub-Study 2: Co-primary endpoints US/FDA: Proportion of participants achieving clinical remission per Crohn's Disease Activity Index (CDAI) at Week 12 | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Crohn's Disease | 980 | 2025-10-01 | 2029-05-14 | in 998 d | 2026-07-01 |
| ABBV | AbbVie | $457.5B | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseNCT06548542Percentage of Participants who Achieve Endoscopic Remission | Phase 2 | Recruiting | Drug: Risankizumab, Lutikizumab, Trosunilimab, Risankizumab, Trosunilimab, ABBV-8736 | Crohn's Disease | 540 | 2024-09-04 | Jan 2030 | ≤ 1,260 d | 2026-06-26 |
| ABBV | AbbVie | $457.5B | Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseNCT06332534Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64 | Phase 3 | Recruiting | Drug: Upadacitinib | Crohn's Disease | 110 | 2024-08-08 | Jun 2027 | ≤ 314 d | 2026-06-24 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World SettingNCT07073079observationalPercentage of Participants who Achieve Corticosteroids (CS) Free Remission | — | Recruiting | — | Crohn's Disease | 250 | 2025-07-14 | Dec 2027 | ≤ 498 d | 2026-06-24 |
| AZN | AstraZeneca | — | An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's DiseaseNCT03759288results2026-06-23CDAI Remission | Phase 2/3 | Terminatedsponsor's stated reason: Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. | Drug: Brazikumab low dose, Brazikumab high dose, Humira®, Placebo | Crohn's Disease, IBD | 89 | 2018-12-07 | 2023-10-18actual | — | 2026-06-23 |
| SNY | Sanofi | — | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's DiseaseNCT07184944Co-primary endpoints US/FDA: Pivotal Maintenance Sub-Study Cohort 1 Proportion of participants achieving clinical remission (CDAI) at Week 40 | Phase 3 | Recruiting | Drug: Duvakitug, Placebo | Crohn's Disease | 751 | 2026-01-22 | 2029-08-13 | in 1,089 d | 2026-06-22 |
| SNY | Sanofi | — | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.NCT06637631Proportion of participants achieving endoscopic response | Phase 2 | Recruiting | Drug: SAR441566, SAR441566 matching Placebo | Crohn's Disease | 260 | 2024-12-10 | 2027-07-21 | in 335 d | 2026-06-12 |
| AZN | AstraZeneca | — | Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyNCT06681324Number of participants with adverse events | Phase 2 | Active, not recruiting | Drug: AZD7798 · Other: Placebo | Crohn's Disease | 24 | 2024-12-11 | 2026-08-20 | today | 2026-06-01 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseNCT05995353Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission | Phase 3 | Recruiting | Drug: Risankizumab, Risankizumab | Crohn's Disease | 110 | 2023-12-11 | Apr 2029 | ≤ 984 d | 2026-05-29 |
| SNY | Sanofi | — | A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)NCT07222189Number of participants with Crohn's Disease with treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) | Phase 2 | Enrolling by invitation | Drug: balinatunfib, balinatunfib-matching placebo | Colitis Ulcerative, Crohn's Disease | 325 | 2026-05-19 | 2030-05-10 | in 1,359 d | 2026-05-22 |
| AZN | AstraZeneca | — | Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.NCT06432764Change from baseline in intestinal SUV/SUVR | Phase 1 | Completed | Drug: AZD7798, [11C]AZ14132516 | Crohn Disease | 9 | 2024-10-16 | 2026-03-27actual | — | 2026-04-14 |
| ABBV | AbbVie | $457.5B | Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)NCT04524611Percentage of Participants Achieving Clinical Remission at Week 24 | Phase 3 | Active, not recruiting | Drug: Risankizumab, Risankizumab, Ustekinumab, Ustekinumab | Crohn's Disease (CD) | 527 | 2020-09-30 | Feb 2028 | ≤ 558 d | 2026-04-13 |
| ABBV | AbbVie | $457.5B | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433NCT03345823Sub-Study 1: Percentage of Participants with Clinical Remission per Crohn's Disease Activity Index (CDAI) | Phase 3 | Active, not recruiting | Drug: Upadacitinib, Placebo for Upadacitinib | Crohn's Disease | 747 | 2018-03-21 | Sep 2027 | ≤ 406 d | 2026-04-09 |
| AZN | AstraZeneca | — | Open-label Extension Study of Brazikumab in Crohn's DiseaseNCT03961815results2026-04-01Adverse Events | Phase 3 | Terminatedsponsor's stated reason: Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. | Drug: Brazikumab Induction Dose, Brazikumab Maintenance Dose | Crohn's Disease, IBD | 18 | 2020-01-06 | 2023-09-19actual | — | 2026-04-01 |
| SNY | Sanofi | — | A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's DiseaseNCT06958536Percentage of participants who achieve endoscopic response at Week 16 | Phase 2 | Recruiting | Drug: SAR442970, Placebo | Crohn's Disease | 99 | 2025-06-03 | 2026-12-17 | in 119 d | 2026-03-27 |
| ABBV | AbbVie | $457.5B | A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World SettingNCT07421258observationalPercentage of Participants Managed Using Treat-to-Target (T2T) | — | Recruiting | — | Crohn's Disease, Ulcerative Colitis | 2,000 | 2026-02-09 | Sep 2026 | ≤ 41 d | 2026-03-27 |
| MESO | Mesoblast, Inc. | — | Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's DiseaseNCT00482092Disease remission (CDAI at or below 150) | Phase 3 | Completed | Drug: Prochymal®, Placebo | Crohn's Disease | 330 | 2007-09-17 | 2014-09-15actual | — | 2026-03-11 |
| MESO | Mesoblast, Inc. | — | Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's DiseaseNCT00543374Duration of clinical benefit (Crohn's disease activity index) | Phase 3 | Completed | Drug: Placebo, PROCHYMAL adult human mesenchymal stem cells | Crohn's Disease | 98 | 2007-09-17 | Jul 2009actual | — | 2026-03-11 |
| MESO | Mesoblast, Inc. | — | Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's DiseaseNCT01233960Disease remission | Phase 3 | Completed | Drug: Prochymal® | Crohn's Disease | 73 | 2010-11-29 | 2014-09-15actual | — | 2026-03-11 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in JapanNCT06023030observationalPercentage of Participants with Drug Related Serious Infections | — | Recruiting | — | Crohn's Disease | 240 | 2023-07-28 | Nov 2026 | ≤ 102 d | 2026-02-24 |
| ABBV | AbbVie | $457.5B | Expanded Access to UpadacitinibNCT04159597expanded access | — | Available | Drug: Upadacitinib | Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis | — | — | — | — | 2026-01-30 |
| ABBV | AbbVie | $457.5B | Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's DiseaseNCT06459297observationalPercentage of participants who reported Serious Adverse Event | — | Completed | — | Ulcerative Colitis, Crohn's Disease | 105 | 2024-06-24 | 2025-12-09actual | — | 2026-01-08 |
| AZN | AstraZeneca | — | AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's DiseaseNCT05452304Number of participants with Adverse Events (AEs) | Phase 1 | Completed | Biological: AZD7798, Placebo | Healthy Subjects, Crohns Disease | 112 | 2022-07-12 | 2024-11-14actual | — | 2025-12-03 |
| ABBV | AbbVie | $457.5B | A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)NCT05394805observationalNumber of Participants with Serious Adverse Events (SAEs) | — | Completed | — | Crohn's Disease | 156 | 2022-06-29 | 2024-12-26actual | — | 2025-11-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.NCT06063967Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission (CDAI < 150) | Phase 3 | Active, not recruiting | Drug: Risankizumab SC, Placebo for risankizumab | Crohn's Disease | 289 | 2023-11-15 | Mar 2027 | ≤ 223 d | 2025-09-09 |
| AZN | AstraZeneca | — | Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's DiseaseNCT06053424Percentage Change in Small Bowel Partition Coefficient (Kp) From Baseline (Positron Emission Tomography [PET]1 Visit) to PET2 Visit | Phase 1 | Completed | Drug: AZD7798, [11C]AZ14132516 | Crohn's Disease | 13 | 2023-09-25 | 2024-10-08actual | — | 2025-08-27 |
| ABBV | AbbVie | $457.5B | Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.NCT05930275observationalTime to Achieve First Clinical Response (CR) per Patient-Reported Outcome 2 (PRO2) (Daily CR-PRO) | — | Active, not recruiting | — | Crohn's Disease | 1,200 | 2024-02-19 | Sep 2028 | ≤ 772 d | 2025-07-17 |
| ABBV | AbbVie | $457.5B | A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)NCT02130362observationalNumber of treatment-emergent AESI per 100 PYs of infections and malignancies | — | Active, not recruiting | — | Crohn's Disease | 1,446 | 2014-08-28 | Nov 2030 | ≤ 1,563 d | 2025-07-16 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK)NCT06126146observationalChange from Baseline in Individual Item Score in Response to Q18 "Overall, how satisfied are you with your current way of taking your medication (self injection)?" in Post-Injection Self-Injection Assessment Questionnaire (SIAQ) | — | Completed | — | Crohn's Disease | 53 | 2023-10-26 | 2024-05-16actual | — | 2025-06-29 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or PsoriasisNCT05796245results2025-06-04observationalIncidence Rate of Serious Infections | — | Completed | — | Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis | 2,207 | 2023-12-01 | 2024-03-14actual | — | 2025-06-04 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)NCT05841537observationalPercentage of Participants with Clinical Remission among Participants with Clinical Response at Month 3 | — | Active, not recruiting | — | Crohn's Disease | 1,019 | 2023-06-09 | Jul 2028 | ≤ 711 d | 2025-05-09 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional TherapyNCT05470985results2025-04-22Percentage of Participants Who Achieve Pediatric Crohn's Disease Activity Index (PCDAI) Score < 10 at Week 64 | Phase 2/3 | Terminatedsponsor's stated reason: Study was terminated due to business reasons. | Drug: Ozanimod | Crohn Disease | 5 | 2023-08-22 | 2024-09-13actual | — | 2025-04-22 |
| PFE | Pfizer | $155.3B | Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)NCT03884439results2025-03-21observationalNumber of Participants With Adverse Drug Reactions | — | Completed | Drug: Infliximab [infliximab biosimilar 3] | Crohn's Disease, Ulcerative Colitis | 428 | 2019-03-18 | 2024-02-02actual | — | 2025-03-21 |
| AMGN | Amgen | $229.9B | Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's DiseaseNCT00102921Crohn's Disease Activity Index score | Phase 2 | Completed | Drug: CCX282-B | Crohn Disease | 70 | Aug 2004 | — | — | 2025-03-06 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's DiseaseNCT00306215Percentage of subjects achieving a clinical response (defined as a decrease from baseline in Crohn's Disease Activity Index [CDAI] score of at least 70) on Day 57 | Phase 2 | Completed | Drug: CCX282-B | Crohn's Disease | 436 | Mar 2006 | Aug 2008actual | — | 2025-03-06 |
| ABBV | AbbVie | $457.5B | Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in BelgiumNCT06581042observationalPercentage of Participants Achieving Clinical Remission as per Partial Adapted Mayo Subscores for Ulcerative Colitis | — | Recruiting | — | Ulcerative Colitis, Crohn's Disease | 280 | 2024-09-27 | Sep 2029 | ≤ 1,137 d | 2025-03-05 |
| ODTX | Odyssey Therapeutics | $1.0B | Phase 1 Study to Investigate OD-07656 in Healthy Adult ParticipantsNCT06206811Adverse event assessed by Safety review committee | Phase 1 | Completed | Drug: OD-07656 | Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis, Spondyloarthritis | 101 | 2024-02-12 | 2024-11-25actual | — | 2025-02-21 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseNCT03926130results2024-12-27Percentage of Adult Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 (Placebo and Mirikizumab) | Phase 3 | Completed | Drug: Mirikizumab, Mirikizumab, Ustekinumab, Ustekinumab, Placebo, Placebo | Crohn's Disease | 1,158 | 2019-07-23 | 2023-08-23actual | — | 2024-12-27 |
| PFE | Pfizer | $155.3B | Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseNCT03395184results2024-10-30Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period | Phase 2 | Completed | Drug: PF-06651600 Placebo, PF-06651600, Placebo PF-06700841, PF-06700841 | Crohn's Disease | 244 | 2018-02-02 | 2023-10-19actual | — | 2024-10-30 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's DiseaseNCT05068284results2024-10-03Percentage of Participants Achieving Endoscopic Response Per Simple Endoscopic Score for Crohn's Disease (SES-CD) | Phase 2 | Terminatedsponsor's stated reason: Strategic considerations | Drug: ABBV-154, Placebo, ABBV-154, Placebo | Crohn's Disease | 176 | 2022-01-31 | 2023-07-20actual | — | 2024-10-03 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisNCT04877990results2024-09-24Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Phase 2 | Completed | Drug: Deucravacitinib | Crohn Disease, Ulcerative Colitis | 67 | 2021-05-07 | 2023-08-29actual | — | 2024-09-24 |
| ABVX | Abivax S.A. | — | Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease PatientsNCT03905109The co-primary objectives of the study are to determine the efficacy of ABX464 in inducing clinical remission and endoscopic improvement after 12 weeks of study treatment in patients with moderate to severe active CD who have inadequate response, loss of | Phase 2/3 | Withdrawnsponsor's stated reason: Study design revised and to be found under new NCT06456593 ABX464-202 | Drug: ABX464, Placebo | Crohn Disease | 0 | 2022-09-19 | 2022-09-19 | — | 2024-07-31 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseNCT03599622results2024-07-03Percent of Participants Achieving Clinical Remission at Week 12 | Phase 2 | Terminatedsponsor's stated reason: Trial terminated because of lack of efficacy in the short term acute phase | Drug: BMS-986165 · Other: Placebo | Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis | 239 | 2018-07-16 | 2022-12-12actual | — | 2024-07-03 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseNCT04254783Maximum Observed Plasma Concentration (Cmax) of Midazolam | Phase 1 | Completed | Drug: Risankizumab, Cytochrome P450 (CYP) Substrates | Ulcerative Colitis (UC), Crohn's Disease | 20 | 2020-05-27 | 2022-10-14actual | — | 2024-07-01 |
| BIIB | Biogen | $31.4B | CD INFORM: Investigating Natalizumab Through Further Observational Research and MonitoringNCT00707512observationalRate of serious and/or clinically significant infections, malignancies, and other SAEs in participants with Crohn's Disease treated with natalizumab | — | Terminatedsponsor's stated reason: Sponsor's decision. | Drug: natalizumab | Crohn's Disease | 87 | 2008-06-30 | 2015-05-28actual | — | 2024-06-03 |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative ColitisNCT03169894results2024-02-26Change From Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) | Phase 1 | Terminatedsponsor's stated reason: Strategic reasons | Drug: MDGN-002 | Crohn Disease, Ulcerative Colitis | 8 | 2017-07-14 | 2021-09-14actual | — | 2024-02-26 |
| PFE | Pfizer | $155.3B | B0151005 Open-Label Extension StudyNCT01345318results2017-03-20Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs | Phase 2 | Completed | Biological: PF-04236921, PF-04236921 | Crohn's Disease | 191 | Jun 2011 | Mar 2016actual | — | 2024-01-12 |
| ABBV | AbbVie | $457.5B | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF TherapyNCT02365649results2023-08-14Percentage of Participants Who Achieve Endoscopic Remission at Week 12/16 | Phase 2 | Completed | Drug: Placebo, ABT-494 | Crohn's Disease | 220 | 2015-03-17 | 2016-11-25actual | — | 2023-12-27 |
| 068270.KS | Celltrion | $30.7B | CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)NCT03945019results2023-10-23Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 | Phase 3 | Completed | Biological: CT-P13 SC (Infliximab) · Other: Placebo SC | Crohn's Disease | 396 | 2019-10-28 | 2022-08-23actual | — | 2023-10-23 |
| BIIB | Biogen | $31.4B | A Real-world Study of Imraldi® UseNCT04089514observationalCandidate Predictors of Persistence on Adalimumab | — | Completed | Drug: Adalimumab | Arthritis, Rheumatoid (RA), Axial Spondyloarthritis (axSpA), Arthritis, Psoriatic (PsA), Crohn's Disease (CD), Colitis, Ulcerative (UC) | 1,000 | 2019-06-30 | 2021-11-30actual | — | 2023-04-18 |
| TBPH | Theravance Biopharma | $880M | Efficacy and Safety of TD-1473 in Crohn's DiseaseNCT03635112results2023-03-13Change From Baseline in Crohn's Disease Activity Index (CDAI) Score | Phase 2 | Terminatedsponsor's stated reason: The study was terminated by the sponsor on 16 November 2021 after a planned review by the Independent Data Monitoring Committee. | Drug: Placebo, TD-1473 | Crohn's Disease | 167 | 2018-11-19 | 2021-12-30actual | — | 2023-03-13 |
| PFE | Pfizer | $155.3B | National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real LifeNCT02925338results2023-01-25observationalPercentage of Participants Without Treatment Failure During 2-Years of Observation | — | Completed | Other: QOL questionaire | Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 1,431 | 2016-10-19 | 2021-04-12actual | — | 2023-01-25 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseNCT00048113 | Phase 3 | Completed | Drug: Alicaforsen | Crohn's Disease | 150 | 2001-01-10 | 2002-04-27actual | — | 2022-12-05 |
| ABBV | AbbVie | $457.5B | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic TherapiesNCT03345849results2022-11-23Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 | Phase 3 | Completed | Drug: Upadacitinib, Placebo for Upadacitinib | Crohn's Disease | 526 | 2017-12-07 | 2021-10-15actual | — | 2022-11-23 |
| BIIB | Biogen | $31.4B | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyNCT03662919observationalPercentage of Participants who are Still Treated with Either Flixabi or Imraldi at 12 Months | — | Completed | Drug: Infliximab, Adalimumab | Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Crohn's Disease, Colitis, Ulcerative | 2,274 | 2018-07-02 | 2022-06-30actual | — | 2022-10-18 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's DiseaseNCT02891226results2022-02-28Percentage of Participants Achieving Endoscopic Response at Week 12 | Phase 2 | Completed | Drug: Mirikizumab, Placebo | Crohn's Disease | 191 | 2016-12-14 | 2018-12-11actual | — | 2022-08-30 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | Alicaforsen (ISIS 2302) in Patients With Active Crohn's DiseaseNCT00048295 | Phase 3 | Completed | Drug: Alicaforsen | Crohn's Disease | 150 | May 2002 | — | — | 2022-08-15 |
| ABBV | AbbVie | $457.5B | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyNCT03345836results2022-08-15Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12 | Phase 3 | Completed | Drug: Matching Placebo for Upadacitinib, Upadacitinib | Crohn's Disease | 624 | 2017-11-29 | 2021-08-11actual | — | 2022-08-15 |
| ABBV | AbbVie | $457.5B | A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseNCT03105128results2022-07-06US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission | Phase 3 | Completed | Drug: placebo for risankizumab, risankizumab IV, risankizumab SC | Crohn's Disease | 931 | 2017-05-10 | 2020-11-09actual | — | 2022-07-06 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic TreatmentNCT03104413results2022-06-14US Specific: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission | Phase 3 | Completed | Drug: placebo for risankizumab IV, risankizumab SC, risankizumab IV | Crohn's Disease | 618 | 2017-12-18 | 2020-11-30actual | — | 2022-06-14 |
| ABBV | AbbVie | $457.5B | Expanded Access to RisankizumabNCT03914261expanded access | — | No longer available | Drug: Risankizumab | Crohn's Disease, Ulcerative Colitis (UC) | — | — | — | — | 2022-05-24 |
| 068270.KS | Celltrion | $30.7B | To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)NCT02326155results2022-02-21observationalNumber and Percentage of Patients Who Experienced Adverse Events of Special Interest (AESI) | — | Terminatedsponsor's stated reason: Terminated | — | Crohn's Disease, Ulcerative Colitis | 470 | 2014-12-08 | 2020-02-28actual | — | 2022-02-21 |
| AMGN | Amgen | $229.9B | Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's DiseaseNCT01150890results2022-01-03Percentage of Participants Who Achieved Clinical Remission at Week 6 | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups | Biological: Brodalumab · Drug: Placebo | Crohn's Disease | 130 | 2010-11-09 | 2011-10-15actual | — | 2022-01-03 |
| AMGN | Amgen | $229.9B | Long-term Safety Study of Brodalumab in Adults With Crohn's DiseaseNCT01199302results2021-12-28Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Terminatedsponsor's stated reason: The study was terminated early based on an imbalance in worsening Crohn's disease in active treatment groups. | Biological: Brodalumab | Crohn's Disease | 67 | 2011-02-02 | 2011-10-18actual | — | 2021-12-28 |
| AZN | AstraZeneca | — | Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.NCT01714726results2019-03-06Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8 | Phase 2 | Completed | Drug: MEDI2070, placebo | Crohn's Disease | 121 | 2013-02-01 | 2014-05-20actual | — | 2021-05-26 |
| AZN | AstraZeneca | — | Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's DiseaseNCT02574637results2020-05-15Percentage of Participants With Crohn's Disease Activity Index (CDAI) Remission at Week 8 | Phase 2 | Terminatedsponsor's stated reason: Study was terminated for business reasons; not due to safety or efficacy concerns. | Drug: Brazikumab IV Infusion, Brazikumab SC Injection, Placebo | Crohn's Disease | 29 | 2016-01-05 | 2017-07-28actual | — | 2021-05-26 |
| AZN | AstraZeneca | — | Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease SubjectsNCT01258205Safety & tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECG, vital signs, or immunogenicity to AMG 139 | Phase 1 | Completed | Drug: AMG 139 | Crohn's Disease | 48 | 2011-02-28 | 2015-02-18actual | — | 2021-05-10 |
| ABBV | AbbVie | $457.5B | Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )NCT02896985observationalExplore the relationship between drug concentration at baseline and recapture of response | — | Completed | — | Crohn's Disease | 98 | 2016-12-16 | 2020-03-11actual | — | 2021-03-09 |
| PFE | Pfizer | $155.3B | Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel DiseaseNCT03801928results2021-03-02observationalAverage Dose of Inflectra at Visit 1 | — | Completed | Drug: Inflectra | Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC) | 118 | 2018-02-23 | 2020-02-07actual | — | 2021-03-02 |
| RDHL | RedHill Biopharma Limited | — | Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's DiseaseNCT03009396results2021-02-24Number of Patients in Remission at Week 16 | Phase 3 | Completed | Drug: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) | Crohn Disease | 54 | 2017-03-18 | 2018-11-13actual | — | 2021-02-24 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's DiseaseNCT02065570results2021-02-18Percentage of Participants Who Achieved Clinical Remission at Week 4 | Phase 3 | Completed | Drug: Adalimumab, Placebo | Crohn's Disease | 514 | 2014-05-01 | 2020-01-30actual | — | 2021-02-18 |
| RDHL | RedHill Biopharma Limited | — | Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's DiseaseNCT01951326results2020-05-01Remission at Week 26 | Phase 3 | Completed | Drug: RHB-104, Placebo | Crohn's Disease | 331 | Sep 2013 | May 2018actual | — | 2020-12-08 |
| ABBV | AbbVie | $457.5B | A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life ConditionsNCT03017014observationalTime to loss of clinical benefit | — | Terminatedsponsor's stated reason: Low enrollment | — | Crohn's Disease | 62 | 2017-09-26 | 2019-10-14actual | — | 2020-10-08 |
| 068270.KS | Celltrion | $30.7B | A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative ColitisNCT02883452results2020-06-09Descriptive Statistics of Area Under the Concentration-time Curve (AUCτ) of Infliximab at Steady State (Part 1) | Phase 1 | Completed | Biological: CT-P13, CT-P13, CT-P13, CT-P13, CT-P13, CT-P13 | Crohn's Disease, Ulcerative Colitis (Part 2 Only) | 181 | 2016-09-29 | 2019-02-04actual | — | 2020-06-09 |
| ABBV | AbbVie | $457.5B | A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's DiseaseNCT02513459results2020-04-24Number of Participants With Adverse Events | Phase 2 | Completed | Drug: Risankizumab 600 mg IV, Risankizumab 180 mg SC | Crohn Disease | 65 | 2015-09-16 | 2019-06-19actual | — | 2020-04-24 |
| MESO | Mesoblast, Inc. | — | Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's DiseaseNCT00294112Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 Points | Phase 2 | Completed | Drug: Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells | Crohn's Disease | 10 | 2006-03-13 | 2006-07-21actual | — | 2020-04-02 |
| MESO | Mesoblast, Inc. | — | Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's DiseaseNCT01510431expanded access | — | No longer available | Drug: PROCHYMAL (remestemcel-L) | Crohn's Disease | — | — | — | — | 2020-03-10 |
| ABBV | AbbVie | $457.5B | Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceNCT03223012observationalProportion of patients with Medication Possession Ratio (MPR)>=80% | — | Completed | — | Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis (AS), Non-radiographic Axial Spondyloarthritis | 116 | 2017-11-15 | 2019-02-28actual | — | 2020-02-24 |
| PFE | Pfizer | $155.3B | Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel DiseaseNCT02539368results2020-02-13observationalDisease Characteristics of Participants: Disease Duration | — | Completed | Drug: CT-P13, Remicade | Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease | 2,565 | 2015-04-22 | 2018-10-31actual | — | 2020-02-13 |
| ABBV | AbbVie | $457.5B | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell LymphomaNCT02087878observationalCollection of Samples | — | Withdrawnsponsor's stated reason: Strategic considerations | — | Crohn's Disease, Ulcerative Colitis (UC), Hepatosplenic T-Cell Lymphoma | 0 | 2014-03-31 | 2019-09-30actual | — | 2019-11-22 |
| ABBV | AbbVie | $457.5B | Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)NCT02750800results2019-11-06observationalMean Change From Baseline in Short Form 36 Version 2.0 (SF-36 V2) Physical Component Summary (PCS) Score at 12 Months | — | Completed | Biological: Adalimumab · Behavioral: AbbVie Care 2.0 | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis | 427 | 2016-04-07 | 2018-04-03actual | — | 2019-11-06 |
| AMGN | Amgen | $229.9B | Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's DiseaseNCT01696396results2019-06-27Percentage of Participants With Remission at Week 8 | Phase 2 | Completed | Drug: Abrilumab, Placebo | Crohn's Disease | 254 | 2012-12-04 | 2014-12-26actual | — | 2019-06-27 |
| ABBV | AbbVie | $457.5B | An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)NCT02451839results2019-06-19observationalChange From Baseline in WHODAS 2.0 Response Score at Month 6 Across All Indications | — | Completed | — | Crohn's Disease, Rheumatoid Arthritis, Psoriasis | 168 | 2015-07-06 | 2017-12-05actual | — | 2019-06-19 |
| GILD | Gilead Sciences | $177.9B | Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's DiseaseNCT02405442results2019-03-28Percentage of Participants Achieving Clinical Response (PRO2 Score ≤ 8) at Week 8 of the Double-Blind Phase | Phase 2 | Terminated | Drug: Andecaliximab, Placebo | Crohn's Disease | 187 | 2015-04-30 | 2016-11-30actual | — | 2019-04-23 |
| ABBV | AbbVie | $457.5B | Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's DiseaseNCT02499783results2019-01-04Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 | Phase 3 | Completed | Biological: adalimumab · Other: placebo | Crohn's Disease | 205 | 2015-08-17 | 2017-05-19actual | — | 2019-01-04 |
| ABBV | AbbVie | $457.5B | Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.NCT02031276results2018-11-23Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Clinical Remission at Week 12 | Phase 2 | Completed | Drug: risankizumab IV, risankizumab SC, Placebo | Crohn Disease | 121 | Feb 2014 | Dec 2015actual | — | 2018-11-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Crohn's Disease is matched — 5 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Crohn's Disease
- Crohn Disease
- Crohn's Disease (CD)
- Crohns Disease
- Moderate to Severe Crohn's Disease
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Crohn's Disease” (a text search, wider than this page)